Bingham Osborn & Scarborough’s DexCom DXCM Stock Holding History

Bingham Osborn & Scarborough’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-55,452	Closed	-$5.71M	–	144
2020 Q3	$5.71M	Sell	55,452 -7,448	-12%	-$778K	0.43%	25
2020 Q2	$6.38M	Buy	62,900 +3,204	+5%	+$287K	0.51%	22
2020 Q1	$4.02M	Sell	59,696 -7,216	-11%	-$449K	0.4%	25
2019 Q4	$3.66M	Sell	66,912 -12,080	-15%	-$573K	0.3%	29
2019 Q3	$2.95M	Sell	78,992 -4,832	-6%	-$188K	0.26%	31
2019 Q2	$3.14M	Buy	83,824 +8,964	+12%	+$282K	0.28%	29
2019 Q1	$2.23M	Hold	74,860	–	–	0.21%	31
2018 Q4	$2.24M	Hold	74,860	–	–	0.23%	31
2018 Q3	$2.68M	Buy	+74,860	New	+$2.32M	0.24%	30

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Bingham Osborn & Scarborough's DXCM Position: Q4 2020 in Review

Bingham Osborn & Scarborough sold out of DexCom (DXCM) in Q4 2020, closing a stake of 55,452 shares — an estimated $5.71M sold.

Bingham Osborn & Scarborough first reported a position in DXCM in Q3 2018 and held it in 9 quarters. The position peaked at $6.38M in Q2 2020. 734 funds tracked by Wall St. Rank hold DXCM as of Q4 2020.

Bingham Osborn & Scarborough reported no remaining DexCom position as of Q4 2020 after selling out during the quarter.
Bingham Osborn & Scarborough sold 55,452 DexCom shares in Q4 2020, an estimated $5.71M.
Bingham Osborn & Scarborough first reported a position in DexCom in Q3 2018 and held it in 9 quarters.
Bingham Osborn & Scarborough's DexCom position peaked at $6.38M in Q2 2020.
734 funds tracked by Wall St. Rank held DexCom as of Q4 2020.

Based on Bingham Osborn & Scarborough's 13F filing for Q4 2020, filed 11 Feb 2021.